Massachusetts
SV Health Investors
SV Health Investors, based in Massachusetts, backs life sciences and healthtech startups from Pre-Seed to Series B, can lead rounds, and has a $269M Dementia Discovery Fund 2.
Entry stagePre-seed, Seed, Series A, Series B
Check sizen/a
Leads roundsYes
FocusLife sciences, Healthtech
Latest fund$269M (2025)$269M Dementia Discovery Fund 2 (2025)
Investing team21 peopleNo activity since Sep
Who you would pitch at SV Health Investors
21 people on the investing team, 12 of them partners who can make the call. Partners are listed first.
Greg MaddenManaging Partner, Medtech & Healthcare GrowthHe focuses on medical device and healthcare services investments.
Kate BinghamManaging Partner, TherapeuticsShe was awarded a DBE in 2021 for chairing the UK Vaccine Taskforce.
Michael BalmuthManaging Partner, Healthcare GrowthHe previously held roles at Summit Partners and Edison Partners, with operating experience at IBM.
Nikola TrbovicManaging Partner, TherapeuticsHe holds a PhD from Columbia University and a Diplom from Goethe University Frankfurt.
Paul LaVioletteManaging Partner, MedtechHe previously held leadership roles at Boston Scientific and other medical device firms.
Tom FlynnManaging Partner, Healthcare GrowthHe previously worked at Ferrer Freeman & Co., GE Capital, and Prudential Investment Corporation, and holds an AB from Holy Cross College and an…
A.J. RossiPartner, Healthcare GrowthHe joined in 2022 and previously was a Principal at Graham Partners.
Christian JungPartner, TherapeuticsHe previously worked at Wellington Partners and High-Tech Gründerfonds, where he made early-stage investments in life sciences companies.
Jamil M. BegPartner, TherapeuticsHe previously worked at 5AM Ventures and holds degrees from the University of Pennsylvania and The Wharton School.
Laurence BarkerPartner, TherapeuticsHe previously led investment management at GSK and worked in business development at Syntaxin and MorphoSys.
Mike RossSenior Partner, TherapeuticsHe previously worked at Genentech and founded Arris Pharmaceutical.
Miles GersonPartner, TherapeuticsHe previously led Takeda Ventures and held operational roles at various life sciences companies.
Andrew CappettaVice President, Healthcare GrowthHe previously worked on corporate development at Thermo Fisher Scientific, focusing on healthcare and life science M&A.
Georgia FrostVice President, TherapeuticsShe previously worked as a life science consultant and postdoctoral fellow, with a PhD in Neuroscience.
Alex Badamchi-ZadehVice President, TherapeuticsHe was promoted to this role in 2024 following the EyeBio exit, recognizing his contribution as a key member of the SV deal team.
Charles DunnPrincipal, TherapeuticsHe helps form and fund companies developing transformational medicines, such as Draig Therapeutics.
Dirk LandgrafPrincipal, TherapeuticsHe commented on Montara's seed expansion and progress.
Jean Rivera IrizarryAssociate, TherapeuticsHe previously worked as a Biotech and Pharma Analyst at Bloomberg Intelligence and holds a PhD in Neuroscience.
Lennart SpindlerAssociate, TherapeuticsHe previously worked as a postdoctoral researcher at the University of Cambridge and co-founded the Queens' College Entrepreneurship Centre.
Vineela KanagalaSenior Associate, Healthcare GrowthPreviously, she worked at Lineage Capital and Putnam Associates.
Eugene HillChairman, Healthcare Growth
Work here and something is wrong? Ask for a correction.
Check size not reported yet.
Bars: how many firms in the atlas report each band. Highlighted: this firm.No recent activity since September 2026. Quiet does not mean closed.
Weekly count of activity updates. Activity is not a confirmed deal.Before you pitch
Ownership target7-10%
Notable investments
InsuletIncyteAmerican Well (Amwell)Bicycle TherapeuticsEvidation Health
In their words
Empowering innovators to improve patients' lives - SV Health InvestorsSV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.svhealthinvestors.com
Send Mode VC your deck
Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckAlert me when SV Health Investors is active
One email when this firm shows new activity. Nothing else.
Firms like SV Health Investors
On these lists
Seed life sciences investors in Massachusetts27Seed healthtech investors in Massachusetts25Series A healthtech investors in Massachusetts24Series A life sciences investors in Massachusetts22Pre-seed life sciences investors in Massachusetts16Series B healthtech investors in Massachusetts11Series B life sciences investors in Massachusetts11Pre-seed healthtech investors in Massachusetts10
Questions
What stage does SV Health Investors invest in?
SV Health Investors reports entry at pre-seed, seed, series a, series b.
How much does SV Health Investors invest?
SV Health Investors has not reported a check size.
Does SV Health Investors lead rounds?
Yes. SV Health Investors says it can lead.
Who are the partners at SV Health Investors?
Greg Madden (Managing Partner, Medtech & Healthcare Growth), Kate Bingham (Managing Partner, Therapeutics), Michael Balmuth (Managing Partner, Healthcare Growth), Nikola Trbovic (Managing Partner, Therapeutics), Paul LaViolette (Managing Partner, Medtech), Tom Flynn (Managing Partner, Healthcare Growth).
Is SV Health Investors active right now?
No recent activity since September 2026.
Work at SV Health Investors? Claim or correct this profile.